Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05731544 · ClinicalTrials.gov registry record · Phase 1
Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)
A Phase 1 study, sponsored by Biomea Fusion.
- Completed
- Registry status
- Phase 1
- Development phase
- 443
- Enrollment target
NCT05731544 is a Phase 1 study that has completed, run by Biomea Fusion. The registered enrollment target is 443 participants.
The verdict
NCT05731544, a Phase 1 study, has completed, sponsored by Biomea Fusion.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 443 participants
- Enrollment target
Study Summary
A Phase 1/ 2 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMF-219, an Oral Covalent Menin Inhibitor, in Healthy Adult Subjects and in Adult Subjects with Type 2 Diabetes Mellitus.
Interventions
- DRUG BMF-219
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 443 participants |
| Start Date | 2022-08-17 |
| Est. Completion | 2025-07-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05731544
The ClinicalTrials.gov registry entry for NCT05731544 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 443 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biomea Fusion, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMF-219 is the first listed.
NCT05731544 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05731544 about?
NCT05731544 is a clinical study titled "Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)". A Phase 1/ 2 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMF-219, an Oral Covalent Menin Inhibitor, in Healthy Adult Subjects and in Adult Subjects with Type 2 Diabetes Mellitus.
What is the current status of trial NCT05731544?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 443 participants. The study started on 2022-08-17. Estimated completion is 2025-07-08.
What interventions are being tested in trial NCT05731544?
The interventions under investigation include: BMF-219 (DRUG).
Who is sponsoring clinical trial NCT05731544?
This trial is sponsored by Biomea Fusion, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.